CN108430482A - 细胞氧化还原水平的控制 - Google Patents

细胞氧化还原水平的控制 Download PDF

Info

Publication number
CN108430482A
CN108430482A CN201680075757.4A CN201680075757A CN108430482A CN 108430482 A CN108430482 A CN 108430482A CN 201680075757 A CN201680075757 A CN 201680075757A CN 108430482 A CN108430482 A CN 108430482A
Authority
CN
China
Prior art keywords
lysate
group
composition
lactobacillus
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680075757.4A
Other languages
English (en)
Chinese (zh)
Inventor
伊丽莎白·麦克纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN108430482A publication Critical patent/CN108430482A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
CN201680075757.4A 2015-11-10 2016-11-10 细胞氧化还原水平的控制 Pending CN108430482A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562253542P 2015-11-10 2015-11-10
US62/253,542 2015-11-10
PCT/US2016/061247 WO2017083470A1 (en) 2015-11-10 2016-11-10 Control of cellular redox levels

Publications (1)

Publication Number Publication Date
CN108430482A true CN108430482A (zh) 2018-08-21

Family

ID=57530816

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680075757.4A Pending CN108430482A (zh) 2015-11-10 2016-11-10 细胞氧化还原水平的控制

Country Status (14)

Country Link
EP (1) EP3373943A1 (cg-RX-API-DMAC7.html)
JP (3) JP2018532814A (cg-RX-API-DMAC7.html)
CN (1) CN108430482A (cg-RX-API-DMAC7.html)
AR (1) AR106660A1 (cg-RX-API-DMAC7.html)
AU (2) AU2016352986A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018009437A2 (cg-RX-API-DMAC7.html)
CA (1) CA3004951A1 (cg-RX-API-DMAC7.html)
EA (1) EA201891142A1 (cg-RX-API-DMAC7.html)
HK (1) HK1252018A1 (cg-RX-API-DMAC7.html)
IL (1) IL259228B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018005745A (cg-RX-API-DMAC7.html)
MY (1) MY203642A (cg-RX-API-DMAC7.html)
SG (2) SG10202112466UA (cg-RX-API-DMAC7.html)
WO (1) WO2017083470A1 (cg-RX-API-DMAC7.html)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108949640A (zh) * 2018-08-22 2018-12-07 江南大学 短双歧杆菌ccfm1025、其发酵食品及其应用
CN109568320A (zh) * 2018-12-13 2019-04-05 中国人民解放军总医院 依曲韦林在制备抗菌消炎药物中的应用
CN109912598A (zh) * 2019-03-27 2019-06-21 四川大学华西医院 防治炎症反应的核苷类衍生物及其应用
CN110079485A (zh) * 2019-05-31 2019-08-02 江南大学 缓解抑郁的乳酸片球菌ccfm6432、其发酵食品及其应用
CN110106111A (zh) * 2019-05-06 2019-08-09 华东理工大学 一种假单胞菌制剂的制备方法、制剂产品及其应用
CN110604098A (zh) * 2019-09-23 2019-12-24 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) 一种类风湿关节炎合并间质性肺病动物模型的构建方法
CN111849805A (zh) * 2020-06-17 2020-10-30 天津科技大学 一种具有抗宫颈癌作用的乳酸片球菌及应用
CN113151036A (zh) * 2018-05-11 2021-07-23 韩国亿诺生物有限公司 具有预防或治疗癌症的效果的新型菌株
CN113304155A (zh) * 2021-05-24 2021-08-27 四川大学华西医院 一种抗肿瘤的药物组合物及其制备方法和用途
CN113712953A (zh) * 2021-10-20 2021-11-30 济宁医学院附属医院 一种用于骨质疏松性骨折快速愈合的药物组合物
CN114174276A (zh) * 2019-08-05 2022-03-11 国际商业机器公司 实现增强的抗微生物活性的组合疗法
WO2022077276A1 (zh) * 2020-10-14 2022-04-21 音芙医药科技(上海)有限公司 烟酰胺单核苷酸与发酵乳杆菌联合在制备缓解皮肤光老化制剂中的应用
CN114381398A (zh) * 2022-01-08 2022-04-22 浙江大学 具有改善酒精性肝病的瑞士乳杆菌zjuids12及其应用
CN115282151A (zh) * 2022-08-23 2022-11-04 黑龙江护理高等专科学校 一种拉米替隆的应用
CN116286669A (zh) * 2023-03-23 2023-06-23 江南大学 一株分泌托拉塞米单克隆抗体的杂交瘤细胞株及其应用
CN117462557A (zh) * 2023-09-26 2024-01-30 大连医科大学附属第一医院 伐尼克兰在制备抗生素增强剂中的应用
US12552933B2 (en) 2019-08-05 2026-02-17 International Business Machines Corporation Polylysine polymers with antimicrobial and/or anticancer activity

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7369992B2 (ja) * 2019-05-13 2023-10-27 株式会社明治 自律神経機能改善用の発酵乳
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
RS68282B1 (en) * 2021-07-09 2026-07-31 Simone Claudio De SPECIES, STRAINS AND COMPOSITIONS OF LACTIC ACID BACTERIA CAPABLE OF MODULATING BODY OXYGENATION BY INCREASE HIF-1ALPHA LEVELS
CN113528399B (zh) * 2021-08-18 2023-02-10 兰州大学 一种具有六价铬离子还原能力的乳酸片球菌及用途
CN116042490B (zh) * 2023-03-03 2023-09-01 善恩康生物科技(苏州)有限公司 一种用于抗疲劳、提高运动能力的复合益生菌及制备方法和应用
EP4438050A1 (en) * 2023-03-31 2024-10-02 Igen Biolab Group AG Postbiotic composition comprising bacterial lysates for oral administration for treating solid tumors
CN121013725A (zh) * 2023-03-31 2025-11-25 西格尼弗有限责任公司 用于治疗实体瘤包含细菌裂解物的口服后生元组合物
EP4527398A1 (en) * 2023-09-22 2025-03-26 Igen Biolab Group AG Therapeutic use of a postbiotic composition in colon and or lung cancer
CN116735756A (zh) * 2023-08-08 2023-09-12 天津辰欣药物研究有限公司 一种气相色谱法测定佩玛贝特起始物料中3-溴丙胺氢溴酸盐杂质的检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104144693A (zh) * 2012-01-16 2014-11-12 E·麦肯纳 用于治疗肝脏疾病和障碍的组合物和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6670244B2 (ja) * 2014-01-07 2020-03-18 バビタ アグラワル 免疫調節組成物及びその使用法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104144693A (zh) * 2012-01-16 2014-11-12 E·麦肯纳 用于治疗肝脏疾病和障碍的组合物和方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
G ZIMMERMAN等: "Post-traumatic anxiety associates with failure of the innate immune receptor TLR9 to evade the pro-inflammatory NFκB pathway", 《TRANSLATIONAL PSYCHIATRY》 *
MARIA DE LOS ANGELES PINEDA等: "A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis", 《MEDICAL SCIENCE MONITOR》 *
P.SIEBLER ET 等: "Immunization with the immunoregulatory saprophytic bacterium, Mycobacterium vaccae, enhances fear extinction in adult male Sprague Dawley rats", 《24TH ANNUAL MEETING OF INTERNATIONAL BEHAVIORAL NEUROSCIENCE SOCIETY》 *
R RAU: "Adalimumab (a fully human anti-tumour necrosis factor a monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials", 《ANNALS OF THE RHEUMATIC DISEASES》 *
XINYAN PENG等: "Protective Effects of Lactobacillus plantarum NDC 75017 Against Lipopolysaccharide-Induced Liver Injury in Mice", 《INFLAMMATION》 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113151036A (zh) * 2018-05-11 2021-07-23 韩国亿诺生物有限公司 具有预防或治疗癌症的效果的新型菌株
CN108949640B (zh) * 2018-08-22 2020-08-04 江南大学 短双歧杆菌ccfm1025、其发酵食品及其应用
CN108949640A (zh) * 2018-08-22 2018-12-07 江南大学 短双歧杆菌ccfm1025、其发酵食品及其应用
CN109568320A (zh) * 2018-12-13 2019-04-05 中国人民解放军总医院 依曲韦林在制备抗菌消炎药物中的应用
CN109912598A (zh) * 2019-03-27 2019-06-21 四川大学华西医院 防治炎症反应的核苷类衍生物及其应用
CN109912598B (zh) * 2019-03-27 2022-09-13 四川大学华西医院 防治炎症反应的核苷类衍生物及其应用
WO2020192665A1 (zh) * 2019-03-27 2020-10-01 四川大学华西医院 防治炎症反应的核苷类衍生物及其应用
CN110106111A (zh) * 2019-05-06 2019-08-09 华东理工大学 一种假单胞菌制剂的制备方法、制剂产品及其应用
CN110079485A (zh) * 2019-05-31 2019-08-02 江南大学 缓解抑郁的乳酸片球菌ccfm6432、其发酵食品及其应用
CN110079485B (zh) * 2019-05-31 2020-09-25 江南大学 缓解抑郁的乳酸片球菌ccfm6432、其发酵食品及其应用
CN114174276A (zh) * 2019-08-05 2022-03-11 国际商业机器公司 实现增强的抗微生物活性的组合疗法
US12552933B2 (en) 2019-08-05 2026-02-17 International Business Machines Corporation Polylysine polymers with antimicrobial and/or anticancer activity
CN110604098B (zh) * 2019-09-23 2021-09-07 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) 一种类风湿关节炎合并间质性肺病动物模型的构建方法
CN110604098A (zh) * 2019-09-23 2019-12-24 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) 一种类风湿关节炎合并间质性肺病动物模型的构建方法
CN111849805A (zh) * 2020-06-17 2020-10-30 天津科技大学 一种具有抗宫颈癌作用的乳酸片球菌及应用
CN111849805B (zh) * 2020-06-17 2022-04-22 天津科技大学 一种具有抗宫颈癌作用的乳酸片球菌及应用
WO2022077276A1 (zh) * 2020-10-14 2022-04-21 音芙医药科技(上海)有限公司 烟酰胺单核苷酸与发酵乳杆菌联合在制备缓解皮肤光老化制剂中的应用
CN113304155A (zh) * 2021-05-24 2021-08-27 四川大学华西医院 一种抗肿瘤的药物组合物及其制备方法和用途
CN113304155B (zh) * 2021-05-24 2023-03-24 四川大学华西医院 一种抗肿瘤的药物组合物及其制备方法和用途
CN113712953B (zh) * 2021-10-20 2022-07-29 济宁医学院附属医院 一种用于骨质疏松性骨折快速愈合的药物组合物
CN113712953A (zh) * 2021-10-20 2021-11-30 济宁医学院附属医院 一种用于骨质疏松性骨折快速愈合的药物组合物
CN114381398B (zh) * 2022-01-08 2022-06-14 浙江大学 具有改善酒精性肝病的瑞士乳杆菌zjuids12及其应用
CN114381398A (zh) * 2022-01-08 2022-04-22 浙江大学 具有改善酒精性肝病的瑞士乳杆菌zjuids12及其应用
CN115282151A (zh) * 2022-08-23 2022-11-04 黑龙江护理高等专科学校 一种拉米替隆的应用
CN115282151B (zh) * 2022-08-23 2023-06-09 黑龙江护理高等专科学校 一种拉米替隆的应用
CN116286669A (zh) * 2023-03-23 2023-06-23 江南大学 一株分泌托拉塞米单克隆抗体的杂交瘤细胞株及其应用
CN116286669B (zh) * 2023-03-23 2023-09-22 江南大学 一株分泌托拉塞米单克隆抗体的杂交瘤细胞株及其应用
CN117462557A (zh) * 2023-09-26 2024-01-30 大连医科大学附属第一医院 伐尼克兰在制备抗生素增强剂中的应用

Also Published As

Publication number Publication date
EA201891142A1 (ru) 2018-11-30
NZ743234A (en) 2025-07-25
EP3373943A1 (en) 2018-09-19
CA3004951A1 (en) 2017-05-18
AU2016352986A1 (en) 2018-06-28
JP2018532814A (ja) 2018-11-08
BR112018009437A2 (en) 2018-12-04
JP2025068627A (ja) 2025-04-28
IL259228B1 (en) 2025-10-01
WO2017083470A1 (en) 2017-05-18
MY203642A (en) 2024-07-11
SG10202112466UA (en) 2021-12-30
SG11201803906PA (en) 2018-06-28
AU2023251534A1 (en) 2023-11-16
MX2018005745A (es) 2018-09-17
IL259228A (en) 2018-07-31
HK1252018A1 (zh) 2019-05-10
JP2023011830A (ja) 2023-01-24
IL259228B2 (en) 2026-02-01
AR106660A1 (es) 2018-02-07

Similar Documents

Publication Publication Date Title
JP2025068627A (ja) 細胞の酸化還元レベルの制御
US12268718B2 (en) Control of cellular redox levels
US11433106B2 (en) Compositions comprising bacterial strains
JP6701276B2 (ja) 細菌株を含む組成物
US11389493B2 (en) Compositions comprising bacterial strains
CN108513544B (zh) 包含细菌菌株的组合物
TWI794139B (zh) 包含細菌菌株之組合物
EP3360558B1 (en) Compositions comprising bacterial strains
TW201709917A (zh) 包含細菌菌株之組合物
US20250312396A1 (en) Control of Cellular Redox Levels
WO2023239728A1 (en) Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
HK1258575B (en) Compositions comprising bacterial strains
HK40030609A (en) Compositions comprising bacterial strains

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1252018

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1252018

Country of ref document: HK